Skyrizi™ (risankizumab-rzaa) – New drug approval
April 23, 2019 - AbbVie announced the FDA approval of Skyrizi (risankizumab-rzaa), for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Download PDF
